InvestSMART

Compumedics Limited (ASX:CMP)

ALERT: Price-sensitive ASX Announcement for CMP
Current share price for CMP : $0.270 -0.01 (-3.57%)+
Announcement
Release
4 Sep 2025 8:38AM
Price at Release
$0.280
Full Release
download
Summary
Compumedics Limited announced that the Somfit®D, a single-use Home Sleep Testing device, has received FDA clearance, instantly doubling its addressable market in the U.S., a market valued at approximately US$240M annually. The company plans to capture 10% to 30% of this market by FY27. The device complements the reusable Somfit®, creating a unique EEG-based diagnostic platform for both high-volume single-use and multi-night reusable markets. This positions Compumedics to expand its market share globally, with clearances already obtained in the USA, Australia, New Zealand, and the EU. The company's dual-platform strategy strengthens its competitive advantage and supports its recurring revenue growth model. Compumedics reaffirms its FY26 financial targets with projected revenues of at least A$70M and an EBITDA of A$9M.
Key Points
  • Somfit®D received FDA clearance, doubling the addressable U.S. market for Compumedics.
  • Compumedics aims to penetrate 10% to 30% of the U.S. Home Sleep Testing market by FY27.
  • The U.S. Home Sleep Testing market is valued at approximately US$240M annually.
  • Somfit®D is a single-use device designed for high-throughput sleep diagnostics.
  • Compumedics' dual-platform strategy spans single-use and reusable sleep testing markets.
  • Compumedics targets global markets, with clearance in the USA, Australia, New Zealand, and the EU.
  • The company reaffirms its FY26 guidance of at least A$70M in revenues and A$9M EBITDA.
  • Compumedics uses a SaaS model for scalable, high-margin recurring revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.